AsianScientist (Sep. 15, 2011) – Dublin-based healthcare provider Covidien today announced the creation of a new R&D center for China, which will be based in Shanghai.
The center, which will be fully functional by July 2012, will house two of Covidien’s emerging market R&D organizations: Tailored Products, which will identify and develop products that are customized to meet the needs of China and other countries in the emerging markets; and Breakthrough Platforms, which will utilize the unique skill sets and expertise of employees in Asia to create and develop new medical device technologies.
“The establishment of this R&D facility is a first for Covidien in China,” said Dr. Dong Wu, Vice President, China R&D, Covidien. “We will be undertaking a range of cutting-edge activities that will create innovative products to help physicians improve the health of the people of China and of other markets worldwide.”
The 25-member R&D staff that Covidien currently employs in Shanghai will increase to more than 300 once the new 100,000-square-foot facility is completed.
“At the core of our R&D facility will be our Laboratory and Operating Theatre Simulation Suites that will enable healthcare professionals to visit the center and be involved in the actual design and development process of future medical devices,” Dr. Wu added.
“This collaborative approach will help us create products that are best suited to the needs of doctors in China and in other countries in Asia and, therefore, will be more likely to produce better patient outcomes.”
To mark the establishment of the R&D facility, a memorandum of understanding was signed between Covidien and the Shanghai Caohejing Hi-Tech Park.
With 2010 revenue of US$10.4 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries.
——
Source: Covidien.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
